Dr Ioana Nicorescu
Dr Amanda Thomson
George Merces
Jack Harrison
Dr Ben Barron-Millar
et al. | Intra-articular injection of autologous tolerogenic dendritic cells modifies the synovial immune landscape in rheumatoid and inflammatory arthritis | 2026 |
|
Professor John Isaacs
Dr Arthur Pratt
| Long-term outcomes of abatacept in individuals at risk of developing rheumatoid arthritis (ALTO): a randomised, double-blind, placebo-controlled trial | 2026 |
|
Dr Karina Patasova
Professor Rachel Knevel
Professor Heather Cordell
Dr Arthur Pratt
| Methods for Prioritizing Causal Genes in Molecular Studies of Human Disease: The State of the Art | 2026 |
|
Dr Josh Bennett
Dr Kieren Hollingsworth
Dr Arthur Pratt
Abbie Degnan
Professor Grainne Gorman
et al. | Skeletal muscle effects of Janus kinase inhibition in rheumatoid arthritis (RAMUS): a single arm, experimental medicine study | 2026 |
|
Dr Ema-Louise Long
Dr James Stanway
Michael White
Nicola Goudie
Julia Phillipson
et al. | Autologous Tolerogenic Dendritic Cells for Rheumatoid Arthritis-2 (AuToDeCRA-2) study: protocol for a single-centre, experimental medicine study investigating the route of delivery and potential efficacy of autologous tolerogenic dendritic cell (TolDC) therapy for rheumatoid arthritis | 2025 |
|
Dr Fiona Rayner
Shaun Hiu
Dr Theophile Bigirumurame
Dr Amy Anderson
Jon Prichard
et al. | Clinical predictors of flare and drug-free remission in rheumatoid arthritis: preliminary results from the prospective BIO-FLARE experimental medicine study | 2025 |
|
Tegan McTaggart
Dr Jing Xuan Lim
Dr Katie Smith
Bronagh Heaney
Dr David McDonald
et al. | Deep phenotyping of T regulatory cells in psoriatic arthritis highlights targetable mechanisms of disease | 2025 |
|
Dr Faye Cooles
Gemma Vidal Pedrola
Najib Naamane
Dr Arthur Pratt
Dr Ben Barron-Millar
et al. | Endogenous Retroelement Activation is Implicated in Interferon-α Production and Anti–Cyclic Citrullinated Peptide Autoantibody Generation in Early Rheumatoid Arthritis | 2025 |
|
Dr Arthur Pratt
| Ethnicity-specific patterns of epigenetic age acceleration in rheumatoid arthritis | 2025 |
|
Dr Arthur Pratt
| Immune checkpoint inhibitor-induced inflammatory arthritis | 2025 |
|
Dr Leher Gumber
Dr Fiona Rayner
Dr Theophile Bigirumurame
Dr Bernard Dyke
Sean Kerrigan
et al. | Patient-reported outcomes as early warning signs of flare following drug cessation in rheumatoid arthritis | 2025 |
|
Dr Arthur Pratt
| Specific features of immune ageing are detected in the earliest stages in rheumatoid arthritis development | 2025 |
|
Professor John Isaacs
Dr Arthur Pratt
Professor Christopher Buckley
Dr Faye Cooles
| Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial | 2024 |
|
Philip Brown
Dr Amy Anderson
Najib Naamane
Dr Dennis Lendrem
Professor John Isaacs
et al. | Adenosine metabolic signature in circulating CD4+ T cells predicts remission in rheumatoid arthritis | 2024 |
|
Anthony McLean
Dr Gary Reynolds
Dr Arthur Pratt
| Leveraging Multi-Tissue, Single-Cell Atlases as Tools to Elucidate Shared Mechanisms of Immune-Mediated Inflammatory Diseases | 2024 |
|
